Innovative solutions

Disruptive strategy to elicit protective immunity against Multidrug-resistant (MDR) Gram-negative bacteria

RemAb is developing a pipeline with different indications. Our most advanced program aims to provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
 

Read more

 

ABOUT US

RemAb Therapeutics is a spin‐off of Bellvitge Biomedical Research Institute (IDIBELL), based in Barcelona.

Read more

PROBLEM

Antimicrobial resistance (AMR) is a growing global threat to human health and economic development.

Read more

PRODUCT

RA-01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.

Read more

 

 

Grants and Awards

 

Grant from

IT Health

European Commission

HeadStart Program

July / 2018

Ref. 2018-HS-0010

Read more

Grant from

Caixa Capital Risk

Obra Social "La Caixa"

CaixaImpulse program

July / 2016

Ref.: CI16-00037

Read more

 

Grant from

CERCA

Generalitat de Catalunya

Fons de Patents Gínjol Program

GAS-1: 2017 – 3rd edition

GAS: 2016 - 1st edition 

Read more